Impact of Hormone Replacement Therapy on Breast Cancer Risk Following Oophorectomy in Women with BRCA Pathogenic Variants - Top-Institutions - MDSpire

Impact of Hormone Replacement Therapy on Breast Cancer Risk Following Oophorectomy in Women with BRCA Pathogenic Variants

  • By

  • Shira Regev-Sadeh

  • Rachel Michaelson-Cohen

  • Dana Madorksy-Feldman

  • Eitan Friedman

  • Shunit Armon

  • Amalfi Qarawani

  • Naama Srebnik

  • Joul Haddad

  • Vered H. Eisenberg

  • Yakir Segev

  • April 8, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Gynecologic Oncology
    • Breast Oncology
    • Genetic Counseling

  • #2

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Gynecologic Oncology
    • Breast Oncology
    • Genetics

  • #3

    University of Texas MD Anderson Cancer Center
    University of Texas MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Gynecologic Oncology
    • Breast Oncology
    • Cancer Genetics

  • #4

    University of Pennsylvania Abramson Cancer Center
    University of Pennsylvania Abramson Cancer Center

    Philadelphia, PA

    Key Differentiators

    • Gynecologic Oncology
    • Breast Oncology
    • Genetics

  • #5

    University of California, San Francisco Helen Diller Family Comprehensive Cancer Center
    University of California, San Francisco Helen Diller Family Comprehensive Cancer Center

    San Francisco, CA

    Key Differentiators

    • Gynecologic Oncology
    • Breast Oncology
    • Cancer Genetics

Original Source(s)

Impact of Hormone Replacement Therapy on Breast Cancer Risk Following Oophorectomy in Women with BRCA Pathogenic Variants

  • by Shira Regev-Sadeh, Rachel Michaelson-Cohen, Dana Madorksy-Feldman, Eitan Friedman, Shunit Armon, Amalfi Qarawani, Naama Srebnik, Joul Haddad, Vered H. Eisenberg, Yakir Segev

  • April 8, 2026

Related Content

Dynamic changes and clinical significance of the gut microbiota and serum metabolites in breast cancer onset, progression and chemotherapy intervention

Recent advances in dissolving microneedles for breast cancer immunotherapy: local delivery and tumor microenvironment remodeling

MIT president: Why so many optimistic scientists are losing heart